Abstract: Background: Immune checkpoint inhibitors are a new promising class of antitumor drugs that have been associated with a number of immune-related Adverse Events (AEs), including musculoskeletal and rheumatic disease.
INTRODUCTION
Immune Checkpoint Inhibitors (ICIs) are a new promising class of anti-tumor drugs that block negative costimulation of T-cells leading to an enhanced anti-tumor immune response. Targets of these therapies include cytotoxic Tlymphocyte associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed death ligand-1 (PD-L1). CTLA-4 and PD-1 are negative regulatory receptors expressed on T-cells. ICIs block the negative interactions between T-cells, antigen presenting cells and tumors, allowing positive costimulation to occur and T-cells to become activated [1] .
In early trials, treatment with both CTLA-4 and PD1 inhibitors showed a remarkable benefit in promoting durable anti-tumor immune responses, and this success led to the approval by the US Food and Drug Administration (FDA) of the monoclonal antibodies ipilimumab (anti-CTLA4), nivolumab (anti-PD1), pembrolizumab (anti-PD1), atezolizumab (anti-PDL1), avelumab (anti-PDL1) and durvalumab (anti-PDL1) for therapeutic use in a variety of cancers, including melanoma, Non-Small-Cell Lung Cancer (NSCLC), head and neck squamous cell carcinoma, renal cell carcinoma, Hodgkin lymphoma, bladder cancer, Merkel cell mab", "anti-programmed death 1 monoclonal antibody", "immune checkpoint inhibitor".
RESULTS
Globally considered, rheumatic and musculoskeletal IRAEs appear to be rarer than other more frequent and burdensome ones, like pneumonitis, hypophysitis and colitis. In a French registry of grade 2 IRAEs occurring in 908 ICItreated patients, 21 (2.3%) experienced an event, excluding arthralgia and myalgia, which are more commonly reported and may rather represent a manifestation of the neoplastic disease itself [4] . In another single-center registry of 400 patients treated with ICIs, only 14 (3.5%) developed rheumatic diseases [5] .
Tables 2 and 3 summarize the findings of the rheumatic and musculoskeletal IRAEs occurring in the ICI-treated patient, as reported by observational studies, case series and case reports.
Arthralgia and Inflammatory Arthritis
Arthralgia is among the most commonly reported AEs, both in clinical trials, observational studies and case reports. The incidence of arthralgia is around 9-12% and 6-8% for patients receiving pembrolizumab and nivolumab, 5% for patients receiving ipilimumab and 11% for patients receiving the combination therapy of nivolumab and ipilimumab [6] .
In a recent systematic review that included 33 clinical trials of all ICIs in different types of cancer, articular pain was the most commonly reported musculoskeletal complaint (1-43% of participants), whereas a true inflammatory arthritis was reported in only five trials, with a prevalence of 1-7% [1] .
The same authors described 13 patients with rheumatologic events following nivolumab, ipilimumab or combination therapy. Inflammatory arthritis was seen in 9 patients, with synovitis confirmed in 4 patients by imaging techniques. Some patients required biologic treatment with etanercept, adalimumab or infliximab to achieve mostly a partial response [7] .
In another retrospective chart review, the authors reported four cases of inflammatory polyarthritis, four patients with oligoarthritis and two with tenosynovitis. Six of them were ANA positive and two had anti-citrullinated protein (anti-CCP) antibodies. All patients were treated with systemic corticosteroids, even at a small dose, and five patients received steroid-sparing agents. Even so, in some of the patients, the joint symptoms persisted for months [8] .
In another retrospective study, conducted in metastatic melanoma treated with pembrolizumab or nivolumab and ipilimumab, 13 .3% of patients developed arthralgia. Most frequently, arthralgia involved large joints (shoulders, knees) in a predominantly symmetrical pattern. Only two patients were seropositive for rheumatoid factor and/or anti-CCP antibodies. Ten patients developed a frank inflammatory arthritis. The majority of patients was treated with Nonsteroidal Anti-inflammatory Drugs (NSAIDs), 23 .1% required additional low-dose corticosteroids and 7.6% of patients received immunosuppressive treatment [9] .
Inflammatory arthritis may affect both large and small joints, and may present with different clinical phenotypes, sometimes as oligoarthritis, sometimes as additive arthritis but also as severe polyarthritis [7, 10] .
A French retrospective study reported that a polyarthritis resembling Rheumatoid Arthritis (RA) developed in six patients receiving ICIs; all six were positive for anti-CCP antibodies and four for rheumatoid factor. The median time to the event after exposure to the drug was 1 month (range 1-9 months). Three patients needed to be treated with diseasemodifying anti-rheumatic drugs (DMARDs); the others received corticosteroids or NSAIDs [11] .
In the French registry including 908 patients, the prevalence of RA was very low (0.2%), whereas that of non-RA inflammatory polyarthritis was slightly higher (1.2%), reaching 2.5% when ICIs were used in combination [4] . In another single-center registry, polyarthritis was seen in 10 out of 400 patients (2.5%), oligoarthritis in one patient and monoarthritis in another one [5] .
Among non-RA inflammatory arthritis, de-novo psoriasis and Psoriatic Arthritis (PsA) were reported to be induced by nivolumab in a few patients with advanced lung cancer [12, 13] . Some of the authors speculated that the induction of psoriasis may correlate with the therapeutic activity of nivolumab, since the occurrence of the psoriatic skin lesions as well as joint symptoms temporally coincided with the regression of lung cancer lesions [14] . In all the cases the patients received corticosteroids and methotrexate with significant benefit.
Pembrolizumab induced a recurring monoarthritis of both knees in a woman with metastatic melanoma [15] but was also responsible for the acute onset of polyarticular inflammatory arthritis [16, 17] . In two of these patients, pembrolizumab caused a severe polyarthritis after 14 and 11 months of therapy, respectively. The first patient had tenosynovitis, synovitis, bone marrow edema, and myositis, whereas the second patient had predominantly synovitis and tenosynovitis. Remission of symptoms was obtained with bisphosphonates and salazopyrin.
In a patient treated with ipilimumab for metastatic melanoma, acute monoarthritis of the knee with a large effusion developed two months after completing ICI therapy and recurred eight months after treatment discontinuation. At both occasions, the patient was given systemic corticosteroid with a moderate benefit. The same patient had pericardial tamponade and bilateral pleural effusions that improved with steroid treatment [18] .
A patient treated with nivolumab developed autoimmune uveitis and Jaccoud's arthropathy. The drug was discontinued and uveitis was treated with intraocular steroids with success, but the treatment strategy of the joint disease was not reported [19] .
Given the extreme variability of clinical presentations and patterns of inflammatory arthritis in patients receiving ICIs, some authors speculated that one group of patients may develop non-specific arthritis due to the up-regulation of the immune system and another group may develop a more specific form of arthritis, like RA or PsA, based on a genetic or environmental predisposition [20] .
Myalgia and Inflammatory Myositis
Myalgia was the second most commonly reported musculoskeletal complaint in clinical trials (2-21% of trial participants) [1] . Nevertheless, several cases of true inflammatory myositis have been described, especially with anti-PD1 treatment.
Treatment with nivolumab has been associated with the development of myositis and myocarditis, even of the severe entity, in a number of case reports and case series, especially in Eastern Asia [21] [22] [23] [24] [25] . A patient treated with nivolumab for advanced colon cancer received a diagnosis of myasthenia gravis and myositis for bilateral ptosis, limb and neck weakness, dyspnea and myalgia developing in two weeks. The patient improved after drug withdrawal and prednisolone and intravenous immunoglobulin administration. Another patient developing severe muscle pain, weakness and shortness of breath after the second dose of nivolumab rapidly improved with drug discontinuation and prednisone administration. In the largest retrospective study, among 12 patients with myasthenia gravis, 4 had concomitant myositis and 3 had myocarditis, with 1 of these patients having both.
In these cases of nivolumab-induced myositis, drug withdrawal and corticosteroid with or without further immunosuppressive therapy were usually effective. Respiratory muscle involvement appeared to be the most fearful complication of nivolumab-induced myositis, causing the death of the patient in one case, even though in another case an improvement was seen after drug discontinuation and corticosteroid administration [26, 27] .
Though IRAEs usually present after some months after drug inception, the onset of severe myositis and myocarditis has been described even after only one dose of nivolumab. This patient improved with corticosteroid treatment, intravenous immunoglobulin and plasma exchange after drug discontinuation [28] .
Finally, nivolumab was also found to induce an autoantibody-positive myositis and myocarditis complicated with a new-onset third-degree atrioventricular block [29] .
Ipilimumab-induced dermatomyositis has been described in a patient with metastatic melanoma. The clinical picture included erythematosus rash with Gottron's papules and proximal muscle weakness. The drug was discontinued and prednisone 1 mg/kg was started, with minimal clinical response [30] .
Another patient developed severe autoimmune myositis following ipilimumab administration, presenting with dysphagia, dysarthria, diffuse muscle weakness and CK elevation. She was treated with intravenous immunoglobulin (400/mg/kg) for ten days and high dose methylprednisolone followed by oral prednisone (1mg/kg daily), with significant benefit and no cancer recurrence [31] .
Ipilimumab has also been associated with the development of severe ocular myositis in two patients with metastatic melanoma. In both cases, the condition improved with the administration of methylprednisolone, mycophenolate mofetil and, in one patient, intravenous immunoglobulin [32] .
A case of pembrolizumab-induced severe bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm was described in a 78-year-old man with metastatic melanoma. This patient developed progressive dyspnea, bilateral ptosis, neck and limb muscle weakness and dysphagia. Prednisone and plasma exchange did not improve his condition and he died for respiratory failure. Interestingly, the autopsy revealed a diffuse necrotic myositis of the diaphragm and a lymphohistiocytic myocarditis [33] .
Other authors reported a case of pembrolizumab-induced myositis, with the muscle biopsy showing multifocal necrosis with adjacent endomysial CD8+ T cell predominant infiltrates, without inclusion bodies. Pembrolizumab was discontinued and the patient was treated first with corticosteroids and then with plasma exchange due to intolerance. The patient experienced a near complete clinical recovery after one month [34] . Among rarer IRAEs, eosinophilic fasciitis has been reported following pembrolizumab treatment in a patient with metastatic melanoma [35] .
Myositis was also described in a patient receiving dual treatment with tremelimumab and durvalumab for non-small cell lung cancer. The complication arose in about one month and corticosteroid treatment provided moderate benefit [10] .
SLE and Sicca Syndrome
Systemic Lupus Erythematosus (SLE) is an autoimmune disease that may involve several organ systems, including skin, joints, heart, lungs, nervous system and kidneys. In our literature review, SLE was rarely found to be associated with ICIs treatment, particularly with ipilimumab.
The first case of lupus-nephritis induced by ipilimumab was described in 2009 in a patient treated for metastatic melanoma. The kidney biopsy showed immunoglobulin and complement complexes in the mesangial space and the serum anti-double-stranded-DNA antibody test was positive, before treatment with prednisone and ipilimumab discontinuation that eventually improved the nephritis [36] .
In a large registry, induction of SLE was reported in only one patient among 524 that experienced an IRAE while on ipilimumab treatment [37] .
A lupus-like cutaneous reaction in the setting of pembrolizumab therapy for metastatic melanoma was described [38] , as well as in a patient receiving nivolumab for metastatic lung cancer [39] . In the latter case, erythematous and non-pruritic papules developed, with histological findings suggestive of a lupus-like drug reaction. The skin rash improved after one month without further treatment other than nivolumab discontinuation.
Dry eyes and dry mouth have been reported as mild AEs in some ICIs clinical trials, with an incidence ranging from 3-24% [1, 40] . In a large French registry reporting only grade 2 IRAEs occurring in ICI-treated patients, the prevalence of true Sjogren's syndrome was 0.3% [4] .
Four out of five patients with sicca syndrome described in a retrospective study had dry mouth without eye involvement following nivolumab, atezolizumab or combination treatment. ANA was positive in two of the five patients, and SSA was positive in one [10] .
In another case series, four patients presented sicca symptoms with severe salivary hypofunction developing on nivolumab, ipilimumab or combination therapy. On ultrasound imaging, one patient had discrete hypoechoic foci occupying more than 50% of her parotid and submandibular glands, as it is usually seen in Sjogren's syndrome. One patient had also pneumonitis and another had interstitial nephritis and colitis. Three of four sicca patients had positive ANA; one patient had low titre La/SSB antibodies; none of the patients had Ro/SSA antibodies [7] .
A patient with metastatic parotid carcinoma developed a sicca syndrome associated with a skin rash on both hands that was identified as Gourgerot-Sjogren like syndrome [41] .
Vasculitis
Isolated cases of vasculitis have been reported following the administration of ICIs (ipilimumab in 3 cases, pembrolizumab in 2 cases) in a large biologic drug registry [37] . Most cases of vasculitis induced by biologics present with isolated cutaneous or neurological (peripheral neuropathy) involvement, and systemic vasculitis appear to be rare. Only two clinical trials of ICIs reported the onset of vasculitis among patients receiving these compounds and in one case a giant cell arteritis was diagnosed [1] .
Among isolated vasculitis, cases of peripheral neuropathy due to histologically proven small vessel vasculitis have been reported. One was induced by pembrolizumab in a 53-year-old woman with seropositive RA and metastatic melanoma. She was treated with high-dose corticosteroids, followed by a gradual tapering, with a complete functional recovery over 6-months and minimal residual paraesthesia [42] .
Even though not all cases of asymmetric polyradiculoneuropathy described in patients on ICIs are secondary to vasculitis, an aspecific microvasculopathy underlying the pathogenesis of the nerve damage has been occasionally described [43] , as well as an acral vascular syndrome presenting with progressive erythema, paresthesia and fingertip pain, but without histological evidence of vasculitis [44] .
Another isolated form of vasculitis involved the uterine circulation, with lymphocytic infiltration and focal fibrin deposition. This patient was receiving ipilimumab for metastatic melanoma and presented with an asymptomatic uterine mass [45] . Nivolumab+ ipilimumab (7) Ipilimumab + pembrolizumab (1) Nivolumab (5) Atezolimumab (1) Durvalumab (1) 
Polymyalgia Rheumatica
Polymyalgia Rheumatica (PMR) almost invariably responds to systemic corticosteroids, even if occurring in patients receiving ICIs.
Some authors reported the development of PMR in two patients with metastatic melanoma being treated with ipilimumab. In one case, a biopsy of the right temporal artery was performed, showing active arteritis, intimal proliferation, and disruption of the internal elastic lamina. Both patients had a brisk response to corticosteroids, with improvement in symptoms and indices of inflammation [46] .
In a French retrospective study, PMR was diagnosed in four patients treated with pembrolizumab and nivolumab ± ipilimumab, and all patients responded to treatment with corticosteroids [11] .
Another French group reported the development of PMR in a patient with non-small cell lung cancer after 13 cycles of nivolumab, with a good response to corticosteroid therapy [47] .
In a case series from the Cleveland Clinic, 3 out of 15 patients evaluated at the Rheumatology Unit had clinical characteristics compatible with PMR including pain and stiffness involving the shoulders, hips and neck, with associated severe morning stiffness. None of them had symptoms concerning for giant cell arteritis [10] . Other patients receiving nivolumab and pembrolizumab developed typical features of PMR that responded well to corticosteroid treatment [48, 49] . Finally, other authors described a variant of PMR, called remitting seronegative symmetrical synovitis with pitting edema syndrome, to be induced by nivolumab in an 80-yearold man with metastatic melanoma [50] .
Sarcoidosis
Several cases of new-onset sarcoidosis were reported in patients being treated with ICIs for metastatic melanoma, including those from a large biologic drugs registry in which sarcoidosis complicated treatment with ipilimumab (13 cases), nivolumab (4 cases) and pembrolizumab (3 cases) [37] . In another retrospective study, 5% out of 147 patients undergoing ipilimumab treatment for melanoma developed sarcoid-like lymphadenopathy after a median interval time of 3.2 months from the start of ipilimumab. The majority of patients had mediastinal and hilar lymphadenopathy except for one patient who had a coexistent intra-abdominal lymphadenopathy [51] . Conversely, in a single center registry, the prevalence of sarcoidosis in patients receiving ICIs was very low (0.2%) [4] .
Notably, some authors observed that in a patient with ICI-induced sarcoidosis the suspension of the drug alone achieved the complete resolution of the metabolically active lymph nodes without the need of additional steroid treatment [52] . Recently, some authors reviewed the cases of 26 patients developing granulomatous/sarcoid-like lesions associated with ICIs. Treatment was discontinued in 38% of patients and only 44% of the patients were treated with systemic steroids. Almost all of the patients demonstrated either resolution or improvement of granulomatous/sarcoid-like lesions irrespective of medical intervention [53] .
In other three cases of ICI-related sarcoidosis-like lymphadenopathy, two occurring during adjuvant ipilimumab for stage III surgically resected melanoma and one during pembrolizumab for metastatic melanoma, histopathological examination revealed non-caseating granulomas. Two of the patients improved with drug discontinuation alone without the need of corticosteroid treatment [54] . Another melanoma patient developed sarcoidosis with bilateral anterior uveitis [55] .
Several other reports confirm that sarcoid-like reactions induced by ICIs are common and often do not require other treatment than drug discontinuation [56] [57] [58] , though in some cases ICI-treatment may be continued without a significant impact on the patient's clinical conditions [59, 60] .
DISCUSSION
Our review suggests that, though rare, musculoskeletal and rheumatic diseases appear to be associated with ICItreatment and demand a prompt recognition to avoid further impact on morbidity and mortality for cancer patients. The approach to the management of these patients may require a tight cooperation between the oncologist and the rheumatologist, that should balance risks and benefits of continuing or withdrawing anti-tumor treatment and evaluate the need for a systemic anti-inflammatory or immunomodulating therapy.
It is difficult to estimate the true incidence and prevalence of musculoskeletal AEs in patients receiving ICIs, given that most of the observational studies are retrospective. Overall, rheumatic complications appear to involve no more than 10% of the ICIs-treated patients. Most of the AEs are mild-to-moderate, except for the more severe forms of myositis that may lead to death due to respiratory involvement.
There are different treatment options for musculoskeletal AEs that vary with the extent and the severity of the disease. Inflammatory arthritis may respond to relatively short courses of NSAIDs or glucocorticoids, but some of the patients may need DMARDs and/or biologic treatment due to refractoriness or disease recurrence upon treatment tapering or discontinuation [61, 62] . PMR usually responds to glucocorticoid treatment that may be tapered as it is usually done in non-cancer patients. Severe forms of myositis may require intravenous immunoglobulin and plasma exchange in addition to corticosteroid treatment. Sarcoidosis and sarcoid-like reactions are usually managed with treatment discontinuation and glucocorticoids.
Even if mild AEs may be managed with drug discontinuation alone, continuing ICI treatment is possible and appears to be safe. Rather, patients that experienced rheumatic AEs while on ICIs showed a higher tumor response rate compared to those who did not [61] . There are several studies reporting the positive association of the tumor response rate with the incidence of different IRAEs in cancer patients [63] .
Since most of the clinical trials of ICIs excluded patients with a preexisting autoimmune disease, little is known about how these drugs may affect this group of patients. Available data on immunotherapy in melanoma patients with preexisting autoimmune diseases are mostly retrospective. Among 30 patients with a variety of autoimmune diseases (from RA to inflammatory bowel diseases) treated with ipilimumab for melanoma, only 8 (27%) had an exacerbation of their autoimmune disease; all flares were medically treated and were observed within the first 6 weeks after the beginning of therapy [64] . A similar retrospective study analyzed melanoma patients who were treated with pembrolizumab or nivolumab after previous failed or intolerant treatment with ipilimumab. Twenty (38%) patients developed a flare of their autoimmune disorder requiring immunosuppression, including seven out of 13 patients with RA. The majority of the flares were relatively mild and only two patients required discontinuation of anti-PD1 treatment [65] .
As far as we know, ICIs administration in a patient with a preexisting autoimmune condition is safe enough to warrant treatment. Rheumatic or autoimmune disease flares can usually be managed only with steroids, with or without discontinuation of the treatment drug, though rarely they may require immunosuppressive treatment [66, 67] .
CONCLUSION
Immune checkpoint inhibitor treatment has been a breakthrough option in several metastatic cancers. As their use is increasing, there is gathering evidence that they may induce rheumatic and musculoskeletal disorders or cause disease flares in patients with a preexisting autoimmune disorder. A rapid recognition and a prompt treatment, possibly with a rheumatologist referral, may help to improve the quality of life of these complicated cancer patients. 
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